Araceli Biosciences Launches Endeavor Live Cell for Kinetic Imaging in Drug Discovery
Araceli Biosciences announced in a press release the launch of Endeavor Live Cell, an imaging system designed for rapid kinetic imaging in large-scale screening campaigns. The system extends Araceli’s imaging platform into dynamic biology, supporting Lab-in-the-Loop workflows used in AI-driven drug discovery.
Endeavor Live Cell enables approximately four-minute imaging intervals across entire 1536-well plates, allowing researchers to monitor cellular processes as they occur. The system supports studies involving compound response, cell health monitoring, phenotypic screening, organoid growth, and other kinetic assays requiring frequent timepoints.
Developed in partnership with Okolab, the system combines Okolab’s live cell incubation and environmental control technology with Araceli’s imaging platform. This integration provides stable environmental conditions along with high-speed imaging and automation compatibility, enabling consistent data collection at scale.
Araceli positions Endeavor Live Cell as part of its imaging infrastructure for AI-enabled drug discovery, aiming to help scientists generate high-quality cellular data for automated experimental workflows.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice Operations Oct 15 Study Tracks 270 Million Clinical AI Queries on OpenEvidence Oct 15 OpenAI Offers US University Labs Free GPT-Rosalind AccessLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
ACROBiosystems Launches ACRO AIx and Rapid Antibody Validation Service
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Illumina Launches BioInsight Platform for Genomic Research
Danaher Plans AI Autonomous Lab for Antibody Research
Inductive Bio launches Beacon-2 to predict human drug doses
Daily AI Brief: the AI news that matters, in your inbox.